Deerfield Management Company, L.P. (Series C) Ventyx Biosciences, Inc. Put Options Transaction History
Deerfield Management Company, L.P. (Series C)
- $5.38 Billion
- Q3 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding VTYX
# of Institutions
125Shares Held
52.9MCall Options Held
35.3KPut Options Held
83K-
Black Rock Inc. New York, NY4.77MShares$8.92 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.46MShares$8.33 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.47MShares$6.48 Million0.0% of portfolio
-
Farallon Capital Management LLC San Francisco, CA3.17MShares$5.93 Million0.03% of portfolio
-
Tang Capital Management LLC San Diego, CA3.1MShares$5.8 Million0.58% of portfolio
About Ventyx Biosciences, Inc.
- Ticker VTYX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,527,200
- Market Cap $106M
- Description
- Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...